Luminor Medical (RISE Life Science) Targets Burgeoning California Cannabis Industry
February 9th, 2018
Exclusive, News, Top News
The U.S. cannabis industry is projected to reach $50 billion in size by 2026 due in large part to California’s decision to legalize adult-use cannabis. While there are many different publicly-traded companies in the state, investors may want to consider those that have near-term commercialization potential.
Luminor Medical Technologies Inc. (CSE: LMT), soon to be called RISE Life Science Corp., aims to capitalize on California’s burgeoning cannabis industry with a focus on medical grade standardized products, already formulated and ready for market. These products will be sold to the medical consumer, as well as the adult health and wellness recreational consumer. The company believes it has desired products which will start to be sold in Q2 of this year in the California marketplace.
California’s Burgeoning Market
The U.S. cannabis industry is projected to reach $50 billion in size by 2026, according to Cowen & Co., driven by the legalization of medical and adult-use cannabis throughout the country. While several states have legalized the drug, it’s difficult to overstate the impact that California has had on the overall market. Many analysts expect the state to become the single largest legal cannabis market in the world following its decision to legalize adult-use cannabis last year.
There are a handful of publicly-traded companies involved in California’s cannabis industry, but most of them are focused on cultivation and remain in the early stages of development. These companies also face hurdles when it comes to regulatory and compliance issues. Of course, the best opportunities may be those with near-term commercialization opportunities since they’re better equipped to capture market share before the market becomes crowded.
Anton Mattadeen, CEO of Luminor Technologies and co-founder of RISE Life Science, stated, “California represents the largest market expression of the cannabis industry in the world. And it’s a dynamic environment filled with efforts on all sides to build an access culture that works. Even the way the regulatory conditions have evolved has enabled creative ideas to thrive and take hold when they make sense. With our focus on creating products designed to connect to the mainstream consumer we view California as the perfect environment for us to introduce ourselves, generate real revenue in the short term, and enter the global marketplace.”
On February 5, Luminor Medical completed the acquisition of RISE Research Inc., which develops cutting-edge hemp and cannabis consumer products for the medical and adult-use markets. These products are largely focused on adult sexual health and wellness markets. The newly created company is rebranding under the name RISE Life Science.
On January 30, RISE announced a strategic partnership with Constance Therapeutics, a San Francisco-based developer and manufacturer of premium medical cannabis products for physician and patient use in California. Under the deal, RISE Life Science will build and manage a retail sales and distribution channel that management anticipates will go into production as early as the second quarter of this year.
“Through our relationship with Constance Therapeutics we are building a collection of brands designed for the new cannabis consumer; able to meet the needs of traditional cannabis customers, while also appealing to 100% of the adult consumer market. By creating products able to target the wider mainstream marketplace, we are positioning the company for early revenue opportunities and sustained long term growth,” said Mr. Mattadeen.
The company plans on addressing both the medical and adult-use markets, but it only plans on selling THC-based products under license to third parties in the United States until federal laws are changed. As a result, the primary manufacturing and marketing focus will be on cannabidiol (CBD) products derived from the highest quality hemp that’s certified as “U.S. Farm Bill Compliant,” enabling the company to stay completely aligned with U.S. federal laws.
Luminor Medical Technologies Inc. (CSE: LMT) represents a compelling investment opportunity in California’s burgeoning cannabis industry. With near-term commercialization plans and a focus on the broader medical market (not just medical marijuana patients), the company enables investors to reap the rewards of the market early on without the regulatory risk of pursuing adult-use cannabis markets directly. Investors may want to keep an eye on the stock given these unique dynamics.
For more information, email or call the RISE Life Science investor relations contact, Mark Komonoski. (403) 255-8483 or (877) 255-8483; [email protected]
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please see our disclaimer below and follow the link to view our full disclosure outlining compensation: https://www.cannabisfn.com/legal-disclaimer/
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.